Malignant News and Research

RSS

Researchers watch armed tumor-seeking immune system cells attack dangerous melanomas in real time

Researchers at UCLA's Jonsson Comprehensive Cancer Center created a large, well armed battalion of tumor-seeking immune system cells and watched, in real time using Positron Emission Tomography (PET), as the special forces traveled throughout the body to locate and attack dangerous melanomas.

13 Jul 2010

Study identifies protein that turns non-malignant tumor into metastatic neuroendocrine tumor

Some types of prostate tumors are more aggressive and more likely to metastasize than others. Nearly one-third of these aggressive tumors contain a small nest of especially dangerous cells known as neuroendocrine-type cells. More rarely, some aggressive prostate tumors are made up entirely of neuroendocrine-type cells. The presence of neuroendocrine-type cancer cells is associated with a poor prognosis, but spotting these rare cells can be like finding a needle in a haystack.

13 Jul 2010

ESMO releases revised set of clinical guidelines for cancer patient care

The European Society for Medical Oncology just released an enhanced and revised set of clinical recommendations designed to help oncologists deliver the best quality care to their patients.

8 Jul 2010

Mathematical model for imaging tumors in breast using microwave tomography

The most popular method of breast cancer detection today is X-ray mammography, which takes images of a compressed breast by low-dose ionizing radiation. However, there are several disadvantages to using X-rays for breast cancer screening, chief among them being the invasivity of radiation and the high costs, which limit their wide use and can deter women from getting them. In addition, depending on the age of the patient and tissue density, X-ray mammograms often result in false positives and negatives.

8 Jul 2010

New research shows cellular changes in fat tissue lead to type 2 diabetes

Cellular changes in fat tissue-not the immune system-lead to the "hyperinflammation" characteristic of obesity-related glucose intolerance and type 2 diabetes, according to new research from the University of Cincinnati.

7 Jul 2010

Multicolor quantum dots can distinguish Reed-Sternberg cells, article shows

The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated.

7 Jul 2010

US WorldMeds launches Revonto for malignant hyperthermia

US WorldMeds is proud to announce the launch of Revonto™ (dantrolene sodium for injection), the first patented scientific advancement in the treatment of malignant hyperthermia (MH). The time to reconstitute dantrolene sodium for injection has been dramatically reduced to approximately 20 seconds or until the solution is clear. Revonto™ retains the cost-savings of the original dantrolene sodium for injection product while offering a significant improvement in pharmacotherapy.

7 Jul 2010

Study finds EPB41L3 'protector gene' inactivated in 65% of ovarian cancers

A new gene that normally protects against ovarian cancer is switched-off in two-thirds of cases of the disease, reveals a study published in the journal Neoplasia today.

3 Jul 2010

Modified Citrus Pectin holds promise against prostate cancer

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the most recent publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

2 Jul 2010

Medicare weighs cost, benefit of covering Dendreon's Provenge for prostate cancer

The announcement that the Centers for Medicare and Medicaid Services would do this analysis "was the latest hurdle in Dendreon's push to get its Provenge treatment used. If the Centers for Medicare and Medicaid Services covers Provenge, that would increase the number of patients eligible and likely force private insurers to do the same.

2 Jul 2010

Highly specific assay developed to detect ERG alterations in prostate cancer

Researchers at the Uniformed Services University of the Health Sciences Center for Prostate Disease Research, in collaboration with investigators at the Armed Forces Institute of Pathology and Walter Reed Army Medical Center, have developed a highly specific assay for the detection of ERG, a protein associated with tumor formations which is present in more than half of all prostate cancers.

1 Jul 2010

Key mechanism present in virgin olive oil protects body against breast cancer: Researchers

Researchers at Universitat Autònoma de Barcelona, led by Dr Eduard Escrich, have discovered a key mechanism by which virgin olive oil, in contrast to other vegetable oils, protects the body against breast cancer.

30 Jun 2010

Asbestos induces cell necrosis, promotes tumor growth

More than 20 million people in the U.S., and many more worldwide, who have been exposed to asbestos are at risk of developing mesothelioma, a malignant cancer of the membranes that cover the lungs and abdomen that is resistant to current therapies.

30 Jun 2010

Scientists uncover variations in X chromosome inactivation in early passages of female embryonic stem cells

Human embryonic stem cells hold great promise for studying and treating disease and for the practice of regenerative medicine. However, more must be learned to ensure the cells that may one day be transplanted into humans are safe.

28 Jun 2010

TLR4 may provide new strategy for treating patients with PDAC: Study

Pancreatic ductal adenocarcinoma is a highly malignant digestive tumor with a very poor prognosis. Hypoxia-inducible transcription factor-1α is involved in malignant progression in many solid tumors, including PDAC, upregulation of HIF-1α accelerates PDAC progression, but the exact regulatory mechanisms of HIF-1αin PDAC has not been unequivocally addressed.

28 Jun 2010

Cyclosporine treatment develops higher de novo cancer risk in liver transplant patients: Researchers

Researchers at Erasmus MC University Medical Centre in The Netherlands found that cyclosporine treatment is a significant risk factor for the development of de novo cancer in liver transplant patients. Full details appear in the July issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

25 Jun 2010

Research on safety of endoscopic piecemeal mucosal resection in treatment of large sessile colorectal polyps

Endoscopic resection of large sessile colorectal polyps is increasingly used as an alternative to surgery, but remains challenging because of its technical difficulty, the high risk of complications such as bleeding or perforation, and the possibility of coexisting malignancy.

25 Jun 2010

Japanese researchers identity useful markers for early diagnosis of CMV gastritis

Cytomegalovirus (CMV) disease is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-SCT), which is widely accepted as a curative therapy for advanced hematological malignancies including leukemia and malignant lymphoma.

25 Jun 2010

New book provides comprehensive review of the functions of p53 family

The p53 tumor suppressor gene, the "guardian of the genome," protects cells against genotoxic stress but is mutated in many cancers. It encodes one of a family of proteins that regulate cell proliferation, differentiation, senescence, and cell death. Mutations in p53 allow cells to escape normal growth controls and thereby contribute to tumor malignancy.

24 Jun 2010

USPTO confirms validity of DUSA's key Levulan PDT patent

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid."

24 Jun 2010

Malignant News and Research

Researchers watch armed tumor-seeking immune system cells attack dangerous melanomas in real time

Study identifies protein that turns non-malignant tumor into metastatic neuroendocrine tumor

ESMO releases revised set of clinical guidelines for cancer patient care

Mathematical model for imaging tumors in breast using microwave tomography

New research shows cellular changes in fat tissue lead to type 2 diabetes

Multicolor quantum dots can distinguish Reed-Sternberg cells, article shows

US WorldMeds launches Revonto for malignant hyperthermia

Study finds EPB41L3 'protector gene' inactivated in 65% of ovarian cancers

Modified Citrus Pectin holds promise against prostate cancer

Medicare weighs cost, benefit of covering Dendreon's Provenge for prostate cancer

Highly specific assay developed to detect ERG alterations in prostate cancer

Key mechanism present in virgin olive oil protects body against breast cancer: Researchers

Asbestos induces cell necrosis, promotes tumor growth

Scientists uncover variations in X chromosome inactivation in early passages of female embryonic stem cells

TLR4 may provide new strategy for treating patients with PDAC: Study

Cyclosporine treatment develops higher de novo cancer risk in liver transplant patients: Researchers

Research on safety of endoscopic piecemeal mucosal resection in treatment of large sessile colorectal polyps

Japanese researchers identity useful markers for early diagnosis of CMV gastritis

New book provides comprehensive review of the functions of p53 family

USPTO confirms validity of DUSA's key Levulan PDT patent

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Latest News